Investing

U.S.-listed Chinese stocks rally as investors turn bullish on reopening shift

Products You May Like

In this article

Alibaba headquarters in Hangzhou, China.
Bloomberg | Bloomberg | Getty Images

Shares of Chinese companies listed in the U.S. jumped Monday after China loosened more Covid restrictions to accelerate the reopening of the economy.

The Invesco Golden Dragon China ETF, which tracks the Nasdaq Golden Dragon China Index, rallied nearly 6% in premarket trading. Alibaba and Pinduoduo popped 4.3% and 3.8%, respectively, while Tencent Music Entertainment gained 3.9%. Chinese electric vehicle names Nio and XPeng rallied 6% and 12%, respectively. Bilibili rallied 16%.

Loading chart…

The index holds 65 companies whose common stocks are publicly traded in the U.S. The majority of their business is conducted within the People’s Republic of China.

The rally came as some big cities including Beijing and Shenzhen are taking steps to ease Covid testing requirements and quarantine rules amid an economic slowdown and public unrest. The move marked a shift from China’s zero-tolerance approach that involved enforce lockdowns and frequent testing for the past two years.

China is poised to announce a nationwide reduction in testing requirements and allowing positive cases and close contacts to isolate at home under certain conditions, Reuters reported, citing sources familiar with the matter.

Morgan Stanley upgraded Chinese stocks to an overweight rating in light of the change in policy. Morgan Stanley had held an equal weight rating on Chinese equities for almost two years.

The Wall Street firm called the recent developments “a confirmed path towards final post-Covid reopening.”

The Hang Seng Tech Index, which represents the 30 largest technology companies listed in Hong Kong, surged 8% in Asia trading hours. China’s onshore and offshore yuan topped $7 against the U.S. dollar for the first time since mid-September. 

– CNBC’s Michael Bloom and Jihye Lee contributed to this report

Products You May Like

Articles You May Like

Pharma is hopeful about Trump’s second term — here’s what to expect for drugmakers
Over 3 million Social Security Fairness Act beneficiaries may wait more than a year for higher payments: Agency
Boeing is working with Elon Musk to deliver Air Force One replacements sooner
Top Wall Street analysts recommend these dividend stocks for stable returns
FDA approves Novo Nordisk’s Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

Leave a Reply

Your email address will not be published. Required fields are marked *